-
Mashup Score: 104
PURPOSE The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor (EGFR)–mutated metastatic non–small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS Patients with disease progression after first- or second-generation EGFR TKI therapy (without EGFR T790M mutation) or osimertinib (with/without T790M mutation) were randomly assigned 1:1 to nivolumab (360 mg once every 3 weeks) plus platinum-doublet chemotherapy (once every 3 weeks) or platinum-doublet chemotherapy alone (once every 3 weeks) for four cycles. Primary end point was progression-free survival (PFS). Secondary end points included 9- and 12-month PFS rates, overall survival (OS), objective response rate (ORR), and duration of response (DOR). RESULTS Overall, 294 patients were randomly assigned. At final analysis (median follow-up, 38.1 months), PFS
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
Leptomeningeal metastasis (LM) is a lethal complication in patients with non-small cell lung cancer (NSCLC) that leads to a poor prognosis [1,2]. The incidence of LM has been increasing, accounting for 3–5 % in molecularly unselected NSCLC patients and up to 9–16 % in epidermal growth factor receptor (EGFR)-mutant lung cancer patients [2–4]. This increased incidence may be attributed to the prolonged survival of patients with EGFR-mutated NSCLC owing to the introduction of EGFR-tyrosine kinase inhibitors (TKIs).
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 79
Leptomeningeal metastasis (LM) is a lethal complication in patients with non-small cell lung cancer (NSCLC) that leads to a poor prognosis [1,2]. The incidence of LM has been increasing, accounting for 3–5 % in molecularly unselected NSCLC patients and up to 9–16 % in epidermal growth factor receptor (EGFR)-mutant lung cancer patients [2–4]. This increased incidence may be attributed to the prolonged survival of patients with EGFR-mutated NSCLC owing to the introduction of EGFR-tyrosine kinase inhibitors (TKIs).
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71First-Line Osimertinib for Uncommon EGFR Mutations and NSCLC - 5 month(s) ago
This nonrandomized phase 2 clinical trial assesses the usefulness of osimertinib in previously untreated patients with metastatic non–small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, excluding exon 20 insertion mutations.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study - 5 month(s) ago
Dacomitinib showed superior progression-free survival (PFS) and overall survival compared to gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations in the ARCHER1050 study. However, because that study did not include patients with brain metastases, the efficacy of dacomitinib in patients with brain metastases has not been clarified.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25
In a European population with non-small cell lung cancer (NSCLC), activating epidermal growth factor receptor (EGFR) mutations occur in about 12–15 % [1,2]. The third generation EGFR tyrosine kinase inhibitor (TKI) osimertinib has become the preferred first line treatment option for common EGFR mutations based on the results of the FLAURA trial demonstrating an improved overall survival (OS) of 38.6 months compared to 31.8 months with first-generation EGFR-TKIs (gefitinib or erlotinib) [3]. In this pivotal trial, only patients with sensitizing EGFR mutations (exon 19 deletion or p.L858R exon 21 mutation) were eligible.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC) - 5 month(s) ago
Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations, after prior therapy. However, the benefits and safety of amivantamab in other EGFR-mutation lung cancer, with or without osimertinib, and with concurrent radiation therapy, are less known.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives - 6 month(s) ago
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85 % of all cases [1], with 20–30 % of patients presenting with stage III disease at diagnosis [2,3], of whom 60–90 % have unresectable disease [4–6]. Epidermal growth factor receptor (EGFR) mutations, which are observed across all NSCLC stages [7], are common oncogenic mutations in unresectable stage III NSCLC. In Asian countries, 15–30 % of patients are reported to have an EGFR mutation; a lower frequency (2–10 %) is reported in patients from Europe and North/South America [8–18].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER - 6 month(s) ago
Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification and other pathways. There is no known involvement of the oncogenic MUC1-C protein in acquired osimertinib resistance.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Treatment options for treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are limited. This study evaluated the safety, tolerability, pharmacokinetics of YK-029A, a third-generation EGFR tyrosine kinase inhibitor, and the preliminary efficacy of YK-029A in treatment-naïve patients with EGFR ex20ins mutation.
Source: www.jto.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Phase III CheckMate 722 @JCO_ASCO: chemo +/- nivolumab in #EGFR NSCLC (post TKI). Addition of immunotherapy with no significant improvement in mPFS (5.6m vs 5.4m, HR 0.75, ns), RR (31% vs 27%), or mOS (19.4m vs 15.9m) but more G3/4 TRAEs (45% vs 29%). https://t.co/AVheIXcybL